Influenza A virus vaccine H5N1 - Omninvest

Drug Profile

Influenza A virus vaccine H5N1 - Omninvest

Alternative Names: Fluval H5N1; Fluval P H5N1; Monovalent influenza A H5N1 vaccine - Omninvest

Latest Information Update: 07 Feb 2014

Price : $50

At a glance

  • Originator Omninvest
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 08 Sep 2008 Launched for Influenza-A virus H5N1 subtype (prevention) in Hungary (IM)
  • 27 Sep 2007 National Institute of Pharmacy issues final marketing authorisation for Influenza A virus vaccine H5N1 in Hungary (first global approval)
  • 14 Mar 2006 Registered for in Influenza A virus infections H5N1 in Hungary (IM) (temporary approval granted)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top